NASDAQ:NBSE NeuBase Therapeutics (NBSE) Stock Price, News & Analysis $0.38 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.38▼$0.3850-Day Range$0.38▼$0.3852-Week Range$0.36▼$4.80VolumeN/AAverage Volume191,869 shsMarket Capitalization$1.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrends Get NeuBase Therapeutics alerts: Email Address Ad Stansberry Research‘Wheels Are Falling Off’ the U.S. Stock Market"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He says what's coming next to the U.S. economy could be much worse than anything he's predicted before. And this time, he says, "The trouble is coming straight for Nvidia and the AI market."Click here to see why. About NeuBase Therapeutics Stock (NASDAQ:NBSE)NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.Read More NBSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBSE Stock News HeadlinesMay 13, 2024 | bizjournals.comNeuBase Therapeutics shareholder meeting adjourns without dissolution approvalMay 6, 2024 | bizjournals.comNeuBase Therapeutics to delist from Nasdaq next weekSeptember 9, 2024 | Stansberry Research (Ad)‘Wheels Are Falling Off’ the U.S. Stock Market"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He says what's coming next to the U.S. economy could be much worse than anything he's predicted before. And this time, he says, "The trouble is coming straight for Nvidia and the AI market."April 6, 2024 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from NasdaqApril 5, 2024 | globenewswire.comNeuBase Therapeutics Announces Receipt of Notice from NasdaqMarch 27, 2024 | msn.comWhy Neubase Therapeutics (NBSE) Shares Are NosedivingMarch 26, 2024 | msn.comNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversMarch 26, 2024 | investorplace.comWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?September 9, 2024 | Stansberry Research (Ad)‘Wheels Are Falling Off’ the U.S. Stock Market"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He says what's coming next to the U.S. economy could be much worse than anything he's predicted before. And this time, he says, "The trouble is coming straight for Nvidia and the AI market."March 25, 2024 | bizjournals.comNeuBase Therapeutics sets shareholder meeting on dissolution planFebruary 26, 2024 | edition.cnn.comNeuBase Therapeutics IncFebruary 20, 2024 | finance.yahoo.comNeuBase Therapeutics, Inc. (NBSE)January 20, 2024 | ca.finance.yahoo.comNeuBase Therapeutics Inc (O7P.BE)December 22, 2023 | bizjournals.comCMU halts licensing agreement with NeuBase TherapeuticsNovember 27, 2023 | finance.yahoo.comPsychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNovember 6, 2023 | morningstar.comNeuBase Therapeutics Inc NBSEOctober 6, 2023 | finance.yahoo.comNeuBase Therapeutics, Inc. (NBSE.MX)September 12, 2023 | benzinga.comMassive Insider Trade At NeuBase TherapeuticsSee More Headlines Receive NBSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/23/2021Today9/09/2024Next Earnings (Estimated)9/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NBSE CUSIPN/A CIK1173281 Webwww.neubasetherapeutics.com Phone(164) 645-1790FaxN/AEmployees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.04 per share Price / Book0.03Miscellaneous Outstanding Shares3,750,000Free Float3,456,000Market Cap$1.42 million OptionableNot Optionable Beta0.95 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Todd P. Branning (Age 54)Interim CEO, CFO & Secretary Comp: $427.44kDr. Dietrich A. Stephan Ph.D. (Age 54)Founder, President & Director Comp: $836.58kKey CompetitorsAptevo TherapeuticsNASDAQ:APVOJaguar HealthNASDAQ:JAGXIM CannabisNASDAQ:IMCCTitan PharmaceuticalsNASDAQ:TTNPBionomicsNASDAQ:BNOXView All CompetitorsInsidersCorp SymetryxSold 129,108 sharesTotal: $185,915.52 ($1.44/share)Corp SymetryxSold 3,376 sharesTotal: $4,861.44 ($1.44/share)View All Insider Transactions NBSE Stock Analysis - Frequently Asked Questions How have NBSE shares performed this year? NeuBase Therapeutics' stock was trading at $0.7401 at the beginning of the year. Since then, NBSE shares have decreased by 48.7% and is now trading at $0.38. View the best growth stocks for 2024 here. How were NeuBase Therapeutics' earnings last quarter? NeuBase Therapeutics, Inc. (NASDAQ:NBSE) posted its quarterly earnings results on Thursday, December, 23rd. The company reported ($4.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.60) by $0.40. When did NeuBase Therapeutics' stock split? NeuBase Therapeutics shares reverse split on the morning of Thursday, June 15th 2023. The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of NeuBase Therapeutics? Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NeuBase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN) and Pfizer (PFE). This page (NASDAQ:NBSE) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSell NVDA Now?Just weeks before last month’s selloff, Citadel – the most successful hedge fund in history – quietly sold 500...Chaikin Analytics | Sponsored‘Wheels Are Falling Off’ the U.S. Stock Market"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He ...Stansberry Research | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredCan Apple’s AI News Make You Rich?September 20th 2024: AI’s “iPhone Moment” Apple is making a major move on Friday, September 20th. And what ...Banyan Hill Publishing | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuBase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuBase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.